Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

NCT04426669 is registered in ClinicalTrials.gov with Intima Bioscience, Inc. as lead sponsor.

NCT NCT04426669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04426669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Lead sponsor
Intima Bioscience, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 15, 2020
Completion date
January 22, 2026
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of gastrointestinal tract, cancer, gastrointestinal, colo-rectal cancer, colon cancer, esophageal cancer, gall bladder cancer, gastrointestinal cancer, gastrointestinal epithelial cancer, gastrointestinal neoplasms, pancreatic cancer, stomach cancer